Expert Opinion on Investigational Drugs

Haemoglobin-based oxygen carriers
pp. 1967-1984(18)
Author: Vandegriff K.D.

Therapeutic developments in peroxisome biogenesis disorders
pp. 1985-1992(8)
Authors: McGuinness M.C.; Wei H.; Smith K.D.

Novel approaches to Behçet’s disease
pp. 1993-2005(13)
Authors: Sakane T.; Takeno M.

Sjögren’s syndrome: current therapies remain inadequate for a common disease
pp. 2007-2016(10)
Author: Fox R.I.

Immunoadsorption, current status and future developments
pp. 2017-2038(22)
Authors: Braun N.; Bosch T.

Potential use of non-classical pathways for the transport of macromolecular drugs
pp. 2039-2050(12)
Authors: Kueltzo L.A.; Middaugh C.R.

Animal models in xenotransplantation
pp. 2051-2068(18)
Authors: Zhang Z.; Bédard E.; Luo Y.; Wang H.; Deng S.; Kelvin D.; Zhong R.

Advances in skin gene therapy
pp. 2069-2083(15)
Authors: Pfützner W.; Vogel J.C.

Cancer treatment with inhibitors of urokinase-type plasminogen activator and plasmin
pp. 2085-2092(8)
Authors: Dunbar S.D.; Ornstein D.L.; Zacharski L.R.

Progress in active-specific immunotherapy of brain malignancies
pp. 2093-2101(9)
Authors: Tjoa B.A.; Salgaller M.L.

The therapeutic potential of flavonoids
pp. 2103-2119(17)
Author: Wang H-K.

Potential use of lipoxygenase inhibitors for cancer chemoprevention
pp. 2121-2138(18)
Authors: Steele V.E.; Holmes C.A.; Hawk E.T.; Kopelovich L.; Lubet R.A.; Crowell J.A.; Sigman C.C.; Kelloff G.J.

Focus on HDL: a new treatment paradigm for athero-thrombotic vascular disease
pp. 2139-2146(8)
Author: Shah P.K.

CTLA4-Ig: a novel immunosuppressive agent
pp. 2147-2157(11)
Authors: Najafian N.; Sayegh M.H.

Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases
pp. 2159-2165(7)
Author: Scatena R.

Ongoing trials with matrix metalloproteinase inhibitors
pp. 2167-2177(11)
Author: Brown P.D.